NIH FUNDING
Evon Medics Secures over $14 Million
in NIH Funding
Since 2018, EvON Medics has been successful in raising over $14 million in non-dilutive funding through the Small Business Innovation Research (SBIR) Program from various institutes of the National Institutes of Health (NIH), including the National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA) and the National Institute of Neurological Disorders and Stroke (NINDS) to fund its Clinical Trials and R&D. This substantial funding portfolio supports the development of breakthrough medical technologies that address critical healthcare challenges, from Alzheimer’s disease to substance use disorders and chronic pain management.
A Portfolio of Transformative Solutions
Our journey of innovation began with the development of the Computerized Olfactory Training (COT) program for Alzheimer’s prevention. Since then, we’ve expanded our portfolio to include multiple cutting-edge solutions, each receiving significant NIH backing:
COT: Pioneering Alzheimer's Prevention
Our flagship COT program has received over $3 million in NIH funding, supporting its development from initial concept through Phase II clinical trials. This FDA-compliant solution uses naturally occurring essential oils and psychophysical tasks to prevent dementia development in individuals with mild cognitive impairment and early Alzheimer’s.
CBOT: Revolutionizing Addiction Treatment
The Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) program has secured nearly $2 million in NIH funding. This innovative, home-based solution targets substance use disorders through pioneering neurological approaches, offering new hope for addiction treatment.
EDITOR: Advancing Digital Health Equity
The Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR) platform has secured approximately $3 million in NIH support. This comprehensive solution addresses the critical need for remote substance use disorder management, particularly focusing on underserved populations and sexual minority groups.
CBOT-P: Transforming Pain Management
Our chronic pain management solution, CBOT-P, has garnered nearly $2 million in NIH funding, with additional Phase II funding pending. This patient-centered approach offers a non-invasive alternative for the millions of Americans suffering from chronic pain conditions.
EMRAST: Early Detection of Cognitive Decline
The Evon Medics Rapid Smell Test (EMRAST) has secured $1.7 million in NIH funding, with additional Phase II funding pending. This portable diagnostic tool represents a breakthrough in early detection and monitoring of Alzheimer’s Disease and Related Dementias.
Looking Forward
Our track record not only demonstrates the scientific validity of our approaches but also our ability to execute complex, multi-year development programs. As we move toward the commercialization of these breakthrough technologies, we continue to build on this foundation of scientific excellence.
At EvON Medics, our motto is clear – to enrich the quality of everyone’s lives through their mental well-being. Join us in transforming the future of neurological health care through innovative, scientifically-validated solutions.